Global Genitourinary Drugs Market Report and Forecast 2024-2032

Global Genitourinary Drugs Market Outlook

The global genitourinary drugs market reached a value of USD 48.46 billion in 2023, driven by the increasing prevalence of urinary tract infections across the globe. The market size is anticipated to grow at a CAGR of 3.1% during the forecast period of 2024-2032 to achieve a value of USD 63.78 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Key Trends in the Market

The genitourinary system comprises of the kidneys, ureter, bladder, urethra, and genital organs which are crucial for reproduction and eliminating waste from the body. The system’s functionality can be impaired by congenital anomalies, infections, iatrogenic injuries, hydronephrosis, cancer, trauma, and inflammation. Globally, there is a surge in demand for genitourinary medications as a result of the increasing number of people who have these conditions. Genitourinary medications are prescribed to treat disorders of the urinary tract, reproductive organs, and excretory system.

• The genitourinary drugs market worldwide is anticipated to grow throughout the forecast period. One of the main factors propelling the market for genitourinary drugs is the increasing prevalence of genitourinary conditions like erectile dysfunction, ovarian cancer, sexually transmitted diseases, bladder cancer, and benign prostatic hyperplasia.

• The leading companies in the market are concentrating on developing medication formulations that assist in treating patients with persistent prostate cancer who have grown resistant to standard chemotherapeutic and hormone treatment agents.

• A number of multinational corporations are working with top biopharmaceutical companies to introduce next-generation treatments and boost their market share. This is helping in the genitourinary drugs market expansion, facilitating a notable increase in the number of pipeline medications that are currently undergoing late-stage clinical studies.

• Further, it is expected that the demand for genitourinary medications would increase in the approaching years due to rising financing for research and development initiatives and advancements in the healthcare infrastructure supported by governmental and non- governmental bodies of many countries.

Global Genitourinary Drugs Market Analysis 

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Based on indication, the market is divided into ovarian cancer, prostate cancer, bladder cancer, cervical cancer, erectile dysfunction, sexually transmitted diseases, interstitial cystitis, and benign prostatic hyperplasia, among others. The market on the basis of product is segmented into urologicals, hormonal therapy drugs, anti-infectives, and gynaecological, among others. The regional markets for genitourinary drugs can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global genitourinary drugs market, covering their competitive landscape and latest developments like mergers, acquisitions, investments, and expansion plans.  

• Bristol-Myers Squibb Company

• Novartis AG

• F. Hoffmann-La Roche Ltd

• Genentech, Inc.

• Pfizer Inc.

• Others

Market Share by Indication

Prostate cancer is anticipated to account for a leading share of the market for genitourinary drugs. This can be attributed to its wide prevalence, and the vast spectrum of treatments used to treat prostate cancer, including immunotherapy drugs, radiopharmaceuticals, and anti-neoplastic medicines. 

The major causes of prostate cancer include an ageing population, obesity, diet, and family history. The genitourinary drugs market supports improved survival rates, slowed disease progression, and minimal side effects. Furthermore, it is projected that invasive operations won't be necessary in the future due to the developments in formulation techniques and next-generation therapies. 

Market Share by Region

The genitourinary drugs market growth is predicted to be dominated by North America because of the region's expanding health care infrastructure, rising awareness of genitourinary problems, and rising need for better therapies and treatments for genitourinary diseases. During the course of the forecast period, the market expansion is anticipated to be fuelled by the rising prevalence of erectile dysfunction or ED in the United States. 

During the projected period, the Asia Pacific market for genitourinary drugs is anticipated to expand at a profitable rate, fuelled by rising awareness in economies like China and India. The significant investments in research and development by major players and persistent efforts to market branded treatments at affordable prices are the driving forces for the market in the region. Rising disposable income will further increases the likelihood of using branded drugs, and ongoing improvements in healthcare infrastructure are also expected to support the market growth in the Asia Pacific. 

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Competitive Landscape

Bristol-Myers Squibb Company, a multinational biopharmaceutical firm with headquarters in New York in the United States researches, develops, and distributes cutting-edge medications that aid patients in overcoming life-threatening illnesses. As part of its dedication to patient care, Bristol Myers Squibb works tirelessly to improve the quality of life for cancer patients as well as to define the future of cancer treatment. The business is renowned for its work in biological and pharmaceutical research.

Novartis AG, a Swiss corporation, is among the biggest producers of medications worldwide. Two significant Swiss pharmaceutical firms, Ciba-Geigy AG and Sandoz AG, combined to form Novartis in 1997. It offers medications for the treatment of infections, immunological disorders, ophthalmic and respiratory illnesses, cancer, cardiovascular diseases, dermatological issues, neurological disorders, and cancer.

F. Hoffmann-La Roche Ltd, a biotechnology business, with headquarters in Switzerland, creates medications and diagnostics to treat serious illnesses. It offers medications to treat conditions like cancer, autoimmune diseases, issues with central nervous systems, eye and vision problems, infectious diseases, and respiratory illnesses. Roche conducts research to find fresh approaches to preventing, diagnosing, and treating illnesses.

Other market players include Genentech, Inc. and Pfizer Inc., among others.

Key Highlights of the Report